Revvity Q4 revenue rises 6% to $772 million; adjusted EPS $1.70 vs. $1.42
Revvity reported fourth-quarter 2025 revenue of $772 million, up 6% from a year earlier, and adjusted EPS from continuing operations of $1.70, up from $1.42. For full-year 2025, revenue rose to $2.86 billion and adjusted EPS reached $5.06, though GAAP EPS fell to $2.07 from $2.20. The company also initiated 2026 guidance, which calls for revenue of $2.96 billion to $2.99 billion and adjusted EPS of $5.35 to $5.45.
Key points
- Q4 2025 GAAP EPS was $0.87 vs. $0.78 a year earlier; GAAP operating income fell to $112 million from $119 million.
- Diagnostics Q4 revenue rose 10% to $390 million; Life Sciences Q4 revenue rose 2% to $382 million.
- Full-year 2025 revenue was $2,856 million vs. $2,755 million in 2024; GAAP EPS was $2.07 vs. $2.20.
- 2026 guidance: revenue of $2.96 billion to $2.99 billion, organic revenue growth of 2% to 3%, and adjusted EPS of $5.35 to $5.45.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 02, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.